13G Filing: Tangiers Global, Llc and Endonovo Therapeutics Inc. (ENDV)

Page 2 of 5 – SEC Filing

CUSIP No. 29272H201 13G Page 2 of 5 Pages
1.

Name of Reporting Person

I.R.S. Identification Nos. of above persons (entities
only).

TANGIERS GLOBAL, LLC.

EIN: 81-1631927

2.

Check the Appropriate Box if a Member of a Group (See
Instructions)

(a) ¨

(b) ¨

3.

SEC Use Only

4.

Citizenship or Place of Organization

Wyoming

Number of

Shares

Beneficially

Owned by

Reporting

Person

With:

5.

Sole Voting Power

19,059,779*

6.

Shared Voting Power

7.

Sole Dispositive Power

19,059,779*

8.

Shared Dispositive Power

9.

Aggregate Amount Beneficially Owned by Each Reporting
Person

19,059,779*

10.

Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)

11.

9.99%*

Percent of Class Represented by Amount in Row (9)

12.

CO

Type of Reporting Person (See Instructions)

FOOTNOTES

*Tangiers has rights, under a Convertible Promissory Note,
to own an aggregate number of shares of the Issuer’s common stock, which, except for a contractual cap on the amount of
outstanding shares of the Issuer’s common stock that Tangiers may own, could exceed such a cap. Tangiers’s ownership
cap is 9.99%. Thus, the number of shares of the Issuer’s common stock beneficially owned by Tangiers as of the date of this
filing was 19,059,779* shares, as calculated in accordance with Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, which
is 9.99% of the 190,788,582 shares that were outstanding on that date.

Follow Endonovo Therapeutics Inc. (LON:ENDV)